{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T23:13:09Z","timestamp":1762125189393},"reference-count":55,"publisher":"Impact Journals, LLC","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,3,29]]},"DOI":"10.18632\/oncotarget.7398","type":"journal-article","created":{"date-parts":[[2016,2,15]],"date-time":"2016-02-15T17:28:59Z","timestamp":1455557339000},"page":"15725-15737","source":"Crossref","is-referenced-by-count":22,"title":["Gamabufotalin triggers c-Myc degradation via induction of WWP2 in multiple myeloma cells"],"prefix":"10.18632","volume":"7","author":[{"given":"Zhenlong","family":"Yu","sequence":"first","affiliation":[{"name":"College of Pharmacy, Academy of Integrative Medicine, Dalian Medical University, Dalian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Biology, College of Chemistry and Life Sciences, Zhejiang Normal University, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Academy of Integrative Medicine, Dalian Medical University, Dalian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sa","family":"Deng","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Academy of Integrative Medicine, Dalian Medical University, Dalian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baojing","family":"Zhang","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Academy of Integrative Medicine, Dalian Medical University, Dalian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaokui","family":"Huo","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Academy of Integrative Medicine, Dalian Medical University, Dalian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobo","family":"Wang","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Academy of Integrative Medicine, Dalian Medical University, Dalian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuping","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochi","family":"Ma","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Academy of Integrative Medicine, Dalian Medical University, Dalian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,2,15]]},"reference":[{"key":"1","article-title":"Promising therapies in multiple myeloma","author":"Anderson","year":"2015","journal-title":"Blood"},{"key":"2","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJMe1407442","article-title":"Current treatment for multiple myeloma","volume":"371","author":"Rosenblatt","year":"2014","journal-title":"The New England journal of medicine"},{"key":"3","first-page":"422","article-title":"Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back","volume":"64","author":"Anderson","year":"2014","journal-title":"CA: a cancer journal for clinicians"},{"key":"4","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2217\/fon.10.2","article-title":"Novel therapeutic targets for multiple myeloma","volume":"6","author":"Raje","year":"2010","journal-title":"Future oncology"},{"key":"5","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1517\/14712598.2013.807337","article-title":"New insights, recent advances, and current challenges in the biological treatment of multiple myeloma","volume":"13","author":"Podar","year":"2013","journal-title":"Expert opinion on biological therapy"},{"key":"6","first-page":"976567","article-title":"Molecularly targeted therapies in multiple myeloma","volume":"2014","author":"Azab","year":"2014","journal-title":"Leukemia research and treatment"},{"key":"7","doi-asserted-by":"publisher","first-page":"739","DOI":"10.18632\/oncotarget.631","article-title":"Oncogene addiction to c-MYC in myeloma cells","volume":"3","author":"Sundan","year":"2012","journal-title":"Oncotarget"},{"key":"8","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood-2011-08-371567","article-title":"Addiction to c-MYC in multiple myeloma","volume":"120","author":"Sundan","year":"2012","journal-title":"Blood"},{"key":"9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12185-013-1291-2","article-title":"Molecular pathogenesis of multiple myeloma: basic and clinical updates","volume":"97","author":"Bergsagel","year":"2013","journal-title":"International journal of hematology"},{"key":"10","first-page":"179","article-title":"Simultaneous quantification of seven major bufadienolides in three traditional Chinese medicinal preparations of chansu by HPLC-DAD","volume":"4","author":"Cui","year":"2009","journal-title":"Natural product communications"},{"key":"11","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3390\/ijms13022025","article-title":"Bufalin Induces Lung Cancer Cell Apoptosis via the Inhibition of PI3K\/Akt Pathway","volume":"13","author":"Liu","year":"2012","journal-title":"International journal of molecular sciences"},{"key":"12","doi-asserted-by":"crossref","first-page":"e47375","DOI":"10.1371\/journal.pone.0047375","article-title":"Critical role of heat shock protein 27 in bufalin-induced apoptosis in human osteosarcomas: a proteomic-based research","volume":"7","author":"Shen","year":"2012","journal-title":"PloS one"},{"key":"13","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/carcin\/bgt060","article-title":"Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K\/Akt\/mTOR pathway","volume":"34","author":"Ye","year":"2013","journal-title":"Carcinogenesis"},{"key":"14","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1007\/s13277-013-1326-6","article-title":"Bufalin exerts antitumor effects by inducing cell cycle arrest and triggering apoptosis in pancreatic cancer cells","volume":"35","author":"Li","year":"2014","journal-title":"Tumour biology"},{"key":"15","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.7314\/APJCP.2012.13.11.5339","article-title":"Anti-tumor activity and apoptosis-regulation mechanisms of bufalin in various cancers: new hope for cancer patients","volume":"13","author":"Li","year":"2012","journal-title":"Asian Pacific journal of cancer prevention"},{"key":"16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/CAD.0b013e3283160fd6","article-title":"PI3K\/Akt is involved in bufalin-induced apoptosis in gastric cancer cells","volume":"20","author":"Liu","year":"2009","journal-title":"Anti-cancer drugs"},{"key":"17","doi-asserted-by":"crossref","first-page":"R82","DOI":"10.1186\/gb-2007-8-5-r82","article-title":"Exon arrays provide accurate assessments of gene expression","volume":"8","author":"Wong","year":"2007","journal-title":"Genome Biol"},{"key":"18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/biostatistics\/4.2.249","article-title":"Exploration, normalization, and summaries of high density oligonucleotide array probe level data","volume":"4","author":"Speed","year":"2003","journal-title":"Biostatistics"},{"key":"19","doi-asserted-by":"crossref","first-page":"Article3","DOI":"10.2202\/1544-6115.1027","article-title":"Linear models and empirical bayes methods for assessing differential expression in microarray experiments","volume":"3","author":"Smyth","year":"2004","journal-title":"Stat Appl Genet Mol Biol"},{"key":"20","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1182\/blood.V92.8.2908","article-title":"Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations","volume":"92","author":"Epstein","year":"1998","journal-title":"Blood"},{"key":"21","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s12253-014-9838-y","article-title":"WWP2: a multifunctional ubiquitin ligase gene","volume":"20","author":"Luo","year":"2014","journal-title":"Pathol Oncol Res"},{"key":"22","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1182\/blood-2009-12-261032","article-title":"Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients","volume":"116","author":"Mulligan","year":"2010","journal-title":"Blood"},{"key":"23","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1158\/1078-0432.CCR-09-2831","article-title":"Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome","volume":"16","author":"Morgan","year":"2010","journal-title":"Clin Cancer Res"},{"key":"24","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1182\/blood-2006-05-026112","article-title":"Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition","volume":"108","author":"Roodman","year":"2006","journal-title":"Blood"},{"key":"25","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/1476-4598-13-203","article-title":"Gamabufotalin, a bufadienolide compound from toad venom, suppresses COX-2 expression through targeting IKKbeta\/NF-kappaB signaling pathway in lung cancer cells","volume":"13","author":"Meng","year":"2014","journal-title":"Mol Cancer"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6514","article-title":"Gamabufotalin, a major derivative of bufadienolide, inhibits VEGF-induced angiogenesis by suppressing VEGFR-2 signaling pathway","author":"Ma","year":"2015","journal-title":"Oncotarget"},{"key":"27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","article-title":"MYC on the path to cancer","volume":"149","author":"Dang","year":"2012","journal-title":"Cell"},{"key":"28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.gene.2011.12.027","article-title":"Regulation of gene transcription by the oncoprotein MYC","volume":"494","author":"Vervoorts","year":"2012","journal-title":"Gene"},{"key":"29","first-page":"51","article-title":"Mechanisms of transcriptional repression by Myc","volume":"302","author":"Eilers","year":"2006","journal-title":"Current topics in microbiology and immunology"},{"key":"30","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1073\/pnas.97.1.228","article-title":"Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma","volume":"97","author":"Kuehl","year":"2000","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"31","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nature08822","article-title":"The landscape of somatic copy-number alteration across human cancers","volume":"463","author":"Greulich","year":"2010","journal-title":"Nature"},{"key":"32","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1146\/annurev.cellbio.16.1.653","article-title":"The Myc\/Max\/Mad network and the transcriptional control of cell behavior","volume":"16","author":"Eisenman","year":"2000","journal-title":"Annual review of cell and developmental biology"},{"key":"33","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/nrc2231","article-title":"Reflecting on 25 years with MYC","volume":"8","author":"Penn","year":"2008","journal-title":"Nature reviews Cancer"},{"key":"34","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.7150\/ijbs.10190","article-title":"Small molecules targeting c-Myc oncogene: promising anti-cancer therapeutics","volume":"10","author":"Zhang","year":"2014","journal-title":"International journal of biological sciences"},{"key":"35","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.biopha.2015.05.019","article-title":"Inhibition of c-Myc by 10058-F4 induces growth arrest and chemosensitivity in pancreatic ductal adenocarcinoma","volume":"73","author":"Li","year":"2015","journal-title":"Biomedicine & pharmacotherapy"},{"key":"36","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1093\/nar\/22.12.2264","article-title":"c-Myc binds to 5\u2032 flanking sequence motifs of the dihydrofolate reductase gene in cellular extracts: role in proliferation","volume":"22","author":"Jalava","year":"1994","journal-title":"Nucleic acids research"},{"key":"37","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/6010","article-title":"Direct activation of TERT transcription by c-MYC","volume":"21","author":"Dalla-Favera","year":"1999","journal-title":"Nature genetics"},{"key":"38","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1073\/pnas.90.13.6175","article-title":"Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2 alpha in response to growth induction by c-myc","volume":"90","author":"Schmidt","year":"1993","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"39","doi-asserted-by":"crossref","first-page":"6274","DOI":"10.1073\/pnas.082005599","article-title":"Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes","volume":"99","author":"Hermeking","year":"2002","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"40","doi-asserted-by":"crossref","first-page":"6635","DOI":"10.1073\/pnas.93.13.6635","article-title":"A novel function for Myc: inhibition of C\/EBP-dependent gene activation","volume":"93","author":"Klempnauer","year":"1996","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"41","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1177\/1947601910377494","article-title":"Therapeutic Targeting of Myc","volume":"1","author":"Vogt","year":"2010","journal-title":"Genes Cancer"},{"key":"42","first-page":"4","article-title":"Therapeutic strategies to inhibit MYC","author":"Bradner","year":"2014","journal-title":"Cold Spring Harbor perspectives in medicine"},{"key":"43","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Bergsagel","year":"2011","journal-title":"Cell"},{"key":"44","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1038\/sj.leu.2404317","article-title":"Aberrant stabilization of c-Myc protein in some lymphoblastic leukemias","volume":"20","author":"Sears","year":"2006","journal-title":"Leukemia"},{"key":"45","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1128\/MCB.20.7.2423-2435.2000","article-title":"c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells","volume":"20","author":"Hann","year":"2000","journal-title":"Molecular and cellular biology"},{"key":"46","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1101\/gad.836800","article-title":"Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability","volume":"14","author":"Nevins","year":"2000","journal-title":"Genes & development"},{"key":"47","first-page":"4","article-title":"MYC degradation","author":"Sears","year":"2014","journal-title":"Cold Spring Harbor perspectives in medicine"},{"key":"48","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.1073\/pnas.1220271110","article-title":"E3 ligase WWP2 negatively regulates TLR3-mediated innate immune response by targeting TRIF for ubiquitination and degradation","volume":"110","author":"Wang","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"49","doi-asserted-by":"crossref","first-page":"e1004751","DOI":"10.1371\/journal.pgen.1004751","article-title":"Notch3 interactome analysis identified WWP2 as a negative regulator of Notch3 signaling in ovarian cancer","volume":"10","author":"Wang","year":"2014","journal-title":"PLoS genetics"},{"key":"50","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/cr.2009.136","article-title":"Wwp2 mediates Oct4 ubiquitination and its own auto-ubiquitination in a dosage-dependent manner","volume":"20","author":"Jin","year":"2010","journal-title":"Cell research"},{"key":"51","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/ncb2240","article-title":"WWP2 is an E3 ubiquitin ligase for PTEN","volume":"13","author":"Chen","year":"2011","journal-title":"Nature cell biology"},{"key":"52","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.emboj.7600217","article-title":"Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7","volume":"23","author":"Nakayama","year":"2004","journal-title":"The EMBO journal"},{"key":"53","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S1097-2765(03)00193-X","article-title":"The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription","volume":"11","author":"Larsson","year":"2003","journal-title":"Molecular cell"},{"key":"54","doi-asserted-by":"crossref","first-page":"6393","DOI":"10.1158\/0008-5472.CAN-12-2664","article-title":"p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction","volume":"72","author":"Yang","year":"2012","journal-title":"Cancer research"},{"key":"55","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.ctrv.2012.03.004","article-title":"Therapeutic approaches to myeloma bone disease: an evolving story","volume":"38","author":"Silvestris","year":"2012","journal-title":"Cancer treatment reviews"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.7398","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T18:27:44Z","timestamp":1589221664000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.7398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,15]]},"references-count":55,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2016,3,29]]}},"alternative-id":["7398","26894970"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.7398","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,15]]}}}